{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:51:54Z","timestamp":1788375114452,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Delayed cerebral ischaemia (DCI) and cerebral vasospasm (CVS) remain major causes of poor outcome in survivors of aneurysmal subarachnoid haemorrhage (aSAH). We aimed to investigate the safety and efficacy of intracisternal administration of nimodipine in patients suffering from symptomatic CVS refractory to treatment with induced hypertension and endovascular vasodilator therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a single-centre, retrospective, observational study including all patients diagnosed with refractory CVS after aSAH treated at our tertiary centre between January 2018 and December 2021 who received continuous intracisternal nimodipine. For nimodipine administration, a catheter was inserted in the optico-carotid cistern via supraorbital craniotomy. Our primary outcome was functional independence measured by the modified Rankin Scale (mRS) at 6\u00a0months. Secondary outcomes included treatment related complications and neurological outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 15 patients in total. Clinical outcome measured by the mRS at 6\u00a0months was good with 93.3% of patients showing mRS\u2009\u2264\u20091 (median mRS 1; range 1\u20134) Eight patients (53%) developed a new CVS-related neurological deficit during intrathecal nimodipine treatment and additionally received bolus intra-arterial nimodipine. Two patients (13%) developed acute subdural\/epidural hematoma postoperatively, which was treated surgically in one patient. In two patients (13%), accidental dislocation of the intrathecal catheter occurred, which warranted re-operation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Continuous intracisternal administration of nimodipine may be a viable rescue therapy option for patients with refractory CVS but is associated with an increased risk of treatment related complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00701-025-06702-5","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:59:39Z","timestamp":1762235979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Continuous intracisternal nimodipine administration as rescue therapy for refractory vasospasm in patients with aneurysmal subarachnoid haemorrhage"],"prefix":"10.1007","volume":"167","author":[{"given":"Mandy D.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Janosovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Mordasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Dobrocky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike I.","family":"Piechowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg C.","family":"Schefold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Murek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Schucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Raabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner J.","family":"Z\u2019Graggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"6702_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.581975","volume":"41","author":"T Al-Khindi","year":"2010","unstructured":"Al-Khindi T, Macdonald RL, Schweizer TA (2010) Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke 41:e519-536. https:\/\/doi.org\/10.1161\/STROKEAHA.110.581975","journal-title":"Stroke"},{"key":"6702_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jns.2018.02.039","volume":"390","author":"F Al-Mufti","year":"2018","unstructured":"Al-Mufti F, Amuluru K, Damodara N, El-Ghanem M, Nuoman R, Kamal N, Al-Marsoummi S, Morris NA, Dangayach NS, Mayer SA (2018) Novel management strategies for medically-refractory vasospasm following aneurysmal subarachnoid hemorrhage. J Neurol Sci 390:44\u201351. https:\/\/doi.org\/10.1016\/j.jns.2018.02.039","journal-title":"J Neurol Sci"},{"key":"6702_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3174\/ajnr.A5024","volume":"38","author":"L Andereggen","year":"2017","unstructured":"Andereggen L, Beck J, Z\u2019Graggen WJ, Schroth G, Andres RH, Murek M, Haenggi M, Reinert M, Raabe A, Gralla J (2017) Feasibility and safety of repeat instant endovascular interventions in patients with refractory cerebral vasospasms. AJNR Am J Neuroradiol 38:561\u2013567. https:\/\/doi.org\/10.3174\/ajnr.A5024","journal-title":"AJNR Am J Neuroradiol"},{"key":"6702_CR4","doi-asserted-by":"publisher","unstructured":"Bederson JB, Connolly ES Jr., Batjer HH, Dacey RG, Dion JE, Diringer MN, Duldner JE Jr., Harbaugh RE, Patel AB, Rosenwasser RH (2009) Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 40:994\u20131025. https:\/\/doi.org\/10.1161\/STROKEAHA.108.191395","DOI":"10.1161\/STROKEAHA.108.191395"},{"key":"6702_CR5","first-page":"1067","volume":"25","author":"A Biondi","year":"2004","unstructured":"Biondi A, Ricciardi GK, Puybasset L, Abdennour L, Longo M, Chiras J, Van Effenterre R (2004) Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: preliminary results. AJNR Am J Neuroradiol 25:1067\u20131076","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"6702_CR6","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1161\/STROKEAHA.119.027396","volume":"51","author":"AP Carlson","year":"2020","unstructured":"Carlson AP, Hanggi D, Wong GK, Etminan N, Mayer SA, Aldrich F, Diringer MN, Schmutzhard E, Faleck HJ, Ng D et al (2020) Single-dose intraventricular nimodipine microparticles versus oral nimodipine for aneurysmal subarachnoid hemorrhage. Stroke 51(4):1142\u20131149. https:\/\/doi.org\/10.1161\/STROKEAHA.119.027396","journal-title":"Stroke"},{"key":"6702_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000002281","volume":"86","author":"GM De Marchis","year":"2016","unstructured":"De Marchis GM, Pugin D, Meyers E, Velasquez A, Suwatcharangkoon S, Park S, Falo MC, Agarwal S, Mayer S, Schmidt JM et al (2016) Seizure burden in subarachnoid hemorrhage associated with functional and cognitive outcome. Neurology 86:253\u2013260. https:\/\/doi.org\/10.1212\/WNL.0000000000002281","journal-title":"Neurology"},{"key":"6702_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000277.pub3","volume":"2007","author":"SM Dorhout Mees","year":"2007","unstructured":"Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J (2007) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007:CD000277. https:\/\/doi.org\/10.1002\/14651858.CD000277.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"6702_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-014-0521-1","volume":"15","author":"JC Durrant","year":"2015","unstructured":"Durrant JC, Hinson HE (2015) Rescue therapy for refractory vasospasm after subarachnoid hemorrhage. Curr Neurol Neurosci Rep 15(2):521. https:\/\/doi.org\/10.1007\/s11910-014-0521-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"6702_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.12.152","author":"ME Eagles","year":"2019","unstructured":"Eagles ME, Tso MK, Macdonald RL (2019) Cognitive impairment, functional outcome, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. World Neurosurg. https:\/\/doi.org\/10.1016\/j.wneu.2018.12.152","journal-title":"World Neurosurg"},{"key":"6702_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1447-6","volume":"20","author":"CL Francoeur","year":"2016","unstructured":"Francoeur CL, Mayer SA (2016) Management of delayed cerebral ischemia after subarachnoid hemorrhage. Crit Care 20:277. https:\/\/doi.org\/10.1186\/s13054-016-1447-6","journal-title":"Crit Care"},{"key":"6702_CR12","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1161\/STROKEAHA.108.544700","volume":"40","author":"JA Frontera","year":"2009","unstructured":"Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N, Connolly ES, Mayer SA (2009) Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke 40:1963\u20131968. https:\/\/doi.org\/10.1161\/STROKEAHA.108.544700","journal-title":"Stroke"},{"key":"6702_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/STROKEAHA.117.017956","volume":"49","author":"CS Gathier","year":"2018","unstructured":"Gathier CS, van den Bergh WM, van der Jagt M, Verweij BH, Dankbaar JW, Muller MC, Oldenbeuving AW, Rinkel GJE, Slooter AJC, Group HS (2018) Induced hypertension for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a randomized clinical trial. Stroke 49:76\u201383. https:\/\/doi.org\/10.1161\/STROKEAHA.117.017956","journal-title":"Stroke"},{"key":"6702_CR14","doi-asserted-by":"publisher","unstructured":"Gilsbach JM. Nimodipine in the prevention of ischaemic deficits after aneurysmal subarachnoid haemorrhage. An analysis of recent clinical studies. Acta Neurochir Suppl (Wien). 1988;45:41\u201350. https:\/\/doi.org\/10.1007\/978-3-7091-9014-2_7","DOI":"10.1007\/978-3-7091-9014-2_7"},{"key":"6702_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.clineuro.2008.05.001","volume":"110","author":"D Hanggi","year":"2008","unstructured":"Hanggi D, Beseoglu K, Turowski B, Steiger HJ (2008) Feasibility and safety of intrathecal nimodipine on posthaemorrhagic cerebral vasospasm refractory to medical and endovascular therapy. Clin Neurol Neurosurg 110:784\u2013790. https:\/\/doi.org\/10.1016\/j.clineuro.2008.05.001","journal-title":"Clin Neurol Neurosurg"},{"key":"6702_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/STROKEAHA.116.014250","volume":"48","author":"D Hanggi","year":"2017","unstructured":"Hanggi D, Etminan N, Aldrich F, Steiger HJ, Mayer SA, Diringer MN, Hoh BL, Mocco J, Faleck HJ, Macdonald RL (2017) Randomized, open-label, phase 1\/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage]). Stroke 48:145\u2013151. https:\/\/doi.org\/10.1161\/STROKEAHA.116.014250","journal-title":"Stroke"},{"key":"6702_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-015-1036-0","volume":"19","author":"H Lantigua","year":"2015","unstructured":"Lantigua H, Ortega-Gutierrez S, Schmidt JM, Lee K, Badjatia N, Agarwal S, Claassen J, Connolly ES, Mayer SA (2015) Subarachnoid hemorrhage: who dies, and why? Crit Care 19:309. https:\/\/doi.org\/10.1186\/s13054-015-1036-0","journal-title":"Crit Care"},{"key":"6702_CR18","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1161\/STROKEAHA.117.018118","volume":"48","author":"JV Lindbohm","year":"2017","unstructured":"Lindbohm JV, Kaprio J, Jousilahti P, Salomaa V, Korja M (2017) Risk factors of sudden death from subarachnoid hemorrhage. Stroke 48:2399\u20132404. https:\/\/doi.org\/10.1161\/STROKEAHA.117.018118","journal-title":"Stroke"},{"key":"6702_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ncpneuro0490","volume":"3","author":"RL Macdonald","year":"2007","unstructured":"Macdonald RL, Pluta RM, Zhang JH (2007) Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 3:256\u2013263. https:\/\/doi.org\/10.1038\/ncpneuro0490","journal-title":"Nat Clin Pract Neurol"},{"key":"6702_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0140-6736(16)30668-7","volume":"389","author":"RL Macdonald","year":"2017","unstructured":"Macdonald RL, Schweizer TA (2017) Spontaneous subarachnoid haemorrhage. Lancet 389:655\u2013666. https:\/\/doi.org\/10.1016\/S0140-6736(16)30668-7","journal-title":"Lancet"},{"key":"6702_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2013.246","volume":"10","author":"RL Macdonald","year":"2014","unstructured":"Macdonald RL (2014) Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol 10:44\u201358. https:\/\/doi.org\/10.1038\/nrneurol.2013.246","journal-title":"Nat Rev Neurol"},{"key":"6702_CR22","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1212\/WNL.0000000000003353","volume":"87","author":"J Mackey","year":"2016","unstructured":"Mackey J, Khoury JC, Alwell K, Moomaw CJ, Kissela BM, Flaherty ML, Adeoye O, Woo D, Ferioli S, De Los Rios La Rosa F et al (2016) Stable incidence but declining case-fatality rates of subarachnoid hemorrhage in a population. Neurology 87:2192\u20132197. https:\/\/doi.org\/10.1212\/WNL.0000000000003353","journal-title":"Neurology"},{"key":"6702_CR23","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1227\/NEU.0b013e31820edd46","volume":"68","author":"C Musahl","year":"2011","unstructured":"Musahl C, Henkes H, Vajda Z, Coburger J, Hopf N (2011) Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage. Neurosurgery 68:1541\u20131547. https:\/\/doi.org\/10.1227\/NEU.0b013e31820edd46","journal-title":"Neurosurgery"},{"key":"6702_CR24","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmj.298.6674.636","volume":"298","author":"JD Pickard","year":"1989","unstructured":"Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, Humphrey PR, Lang DA, Nelson R, Richards P (1989) Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 298:636\u2013642. https:\/\/doi.org\/10.1136\/bmj.298.6674.636","journal-title":"BMJ"},{"key":"6702_CR25","first-page":"1778","volume":"25","author":"AA Rabinstein","year":"2004","unstructured":"Rabinstein AA, Friedman JA, Nichols DA, Pichelmann MA, McClelland RL, Manno EM, Atkinson JL, Wijdicks EF (2004) Predictors of outcome after endovascular treatment of cerebral vasospasm. AJNR Am J Neuroradiol 25:1778\u20131782","journal-title":"AJNR Am J Neuroradiol"},{"key":"6702_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clineuro.2017.10.012","volume":"163","author":"PC Reinacher","year":"2017","unstructured":"Reinacher PC, Coenen VA, Kraeutle R, Scheiwe C, Jabbarli R, Roelz R (2017) Feasibility of stereotactic catheter ventriculocisternostomy for cisternal lavage therapy in patients with subarachnoid hemorrhage. Clin Neurol Neurosurg 163:94\u2013102. https:\/\/doi.org\/10.1016\/j.clineuro.2017.10.012","journal-title":"Clin Neurol Neurosurg"},{"key":"6702_CR27","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1161\/STROKEAHA.117.018397","volume":"48","author":"R Roelz","year":"2017","unstructured":"Roelz R, Coenen VA, Scheiwe C, Niesen WD, Egger K, Csok I, Kraeutle R, Jabbarli R, Urbach H, Reinacher PC (2017) Stereotactic catheter ventriculocisternostomy for clearance of subarachnoid hemorrhage: a matched cohort study. Stroke 48:2704\u20132709. https:\/\/doi.org\/10.1161\/STROKEAHA.117.018397","journal-title":"Stroke"},{"key":"6702_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05208-6","volume":"22","author":"R Roelz","year":"2021","unstructured":"Roelz R, Schubach F, Coenen VA, Jenkner C, Scheiwe C, Grauvogel J, Niesen WD, Urbach H, Taschner C, Seufert J et al (2021) Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial. Trials 22:285. https:\/\/doi.org\/10.1186\/s13063-021-05208-6","journal-title":"Trials"},{"key":"6702_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1161\/STROKEAHA.120.029538","volume":"52","author":"B Schatlo","year":"2021","unstructured":"Schatlo B, Fung C, Stienen MN, Fathi AR, Fandino J, Smoll NR, Zumofen D, Daniel RT, Burkhardt JK, Bervini D et al (2021) Incidence and outcome of aneurysmal subarachnoid hemorrhage: the Swiss study on subarachnoid hemorrhage (Swiss SOS). Stroke 52:344\u2013347. https:\/\/doi.org\/10.1161\/STROKEAHA.120.029538","journal-title":"Stroke"},{"key":"6702_CR30","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1161\/STROKEAHA.118.022536","volume":"50","author":"S Suwatcharangkoon","year":"2019","unstructured":"Suwatcharangkoon S, De Marchis GM, Witsch J, Meyers E, Velazquez A, Falo C, Schmidt JM, Agarwal S, Connolly ES, Claassen J et al (2019) Medical treatment failure for symptomatic vasospasm after subarachnoid hemorrhage threatens long-term outcome. Stroke 50:1696\u20131702. https:\/\/doi.org\/10.1161\/STROKEAHA.118.022536","journal-title":"Stroke"},{"key":"6702_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3171\/jns.2005.103.1.0009","volume":"103","author":"P Vajkoczy","year":"2005","unstructured":"Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P (2005) Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9\u201317. https:\/\/doi.org\/10.3171\/jns.2005.103.1.0009","journal-title":"J Neurosurg"},{"key":"6702_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0140-6736(07)60153-6","volume":"369","author":"J van Gijn","year":"2007","unstructured":"van Gijn J, Kerr RS, Rinkel GJ (2007) Subarachnoid haemorrhage. Lancet 369:306\u2013318. https:\/\/doi.org\/10.1016\/S0140-6736(07)60153-6","journal-title":"Lancet"},{"key":"6702_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11206197","author":"H Vatter","year":"2022","unstructured":"Vatter H, Guresir E, Konig R, Durner G, Kalff R, Schuss P, Mayer TE, Konczalla J, Hattingen E, Seifert V et al (2022) Invasive diagnostic and therapeutic management of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (IMCVS)-a phase 2 randomized controlled trial. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11206197","journal-title":"J Clin Med"},{"key":"6702_CR34","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/STROKEAHA.106.477976","volume":"38","author":"S Weidauer","year":"2007","unstructured":"Weidauer S, Lanfermann H, Raabe A, Zanella F, Seifert V, Beck J (2007) Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke 38:1831\u20131836. https:\/\/doi.org\/10.1161\/STROKEAHA.106.477976","journal-title":"Stroke"},{"key":"6702_CR35","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.04.005","volume":"22","author":"YP Zhang","year":"2013","unstructured":"Zhang YP, Shields LB, Yao TL, Dashti SR, Shields CB (2013) Intrathecal treatment of cerebral vasospasm. J Stroke Cerebrovasc Dis 22:1201\u20131211. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2012.04.005","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-025-06702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-025-06702-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-025-06702-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:02:42Z","timestamp":1762279362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-025-06702-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6702"],"URL":"https:\/\/doi.org\/10.1007\/s00701-025-06702-5","relation":{},"ISSN":["0942-0940"],"issn-type":[{"value":"0942-0940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data used for this analysis were gathered as part of clinical routine. Due to the severity of SAH in the patients included in this project, taking consent at admission was not always possible. Furthermore, due to long-term sequelae and psychological burden caused by the initial SAH, taking consent from all patients was not reasonable. In line with national guidelines, written informed consent was therefore not sought from all patients. However, patients with documented refusal of participation in research projects were excluded from the analysis. Approval for this study was obtained from the local ethics committee on human research (Kantonale Ethikkommission, KEK, Bern, Switzerland, BASEC-Nr: 2022\u201300310) and the study conformed to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}